News

PMA Insights: Week 7

17/02/2023
  • CEPs Annual Report indicates reduced time to market access
  • The FDA’s Biosimilar User Fee Amendments III (BsUFA III)
15022023-News-Digest-Wk-7Download

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding Gene Therapy & ATMPs HTA PMA Trends Pricing

Share this article

Related articles

Articles
22.10.2026
From JCA convergence to national divergence: Diagn...

Joint Clinical Assessment (JCA) provides a common EU-level clinical assessment, but national HTA and...

Read more
Articles
05.10.2026
Forecasting PICOs early: What if your final eviden...

Manufacturers should not wait for final HTA scopes to test whether their evidence package can addres...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch